Emergency management of acute stroke ACA guidelines detail 2026
Reading File
Finding Sources
Searching PubMed
"acute ischemic stroke" AND "guidelines" AND "emergency management"
Searching the Web
AHA ASA acute ischemic stroke guidelines 2025 2026 emergency management update
Reading Web Page
https://www.rejoyhealth.com/blog/2026-aha-asa-guideline-for-…
Reading Web Page
https://newsroom.heart.org/news/new-guideline-expands-stroke…
Finding Sources
Finding Sources
Searching PubMed
"acute ischemic stroke" AND "tenecteplase" AND "thrombectomy"
Reading File
I now have comprehensive data from the 2026 AHA/ASA guideline, the textbook, and recent evidence. Let me compile the full answer.
2026 AHA/ASA Guidelines: Emergency Management of Acute Ischemic Stroke
Source: Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. American Heart Association/American Stroke Association. Stroke. Published January 26, 2026. doi:10.1161/STR.0000000000000513
This guideline replaces the 2018 edition and its 2019 update, and is the most comprehensive revision to date - covering over 100 pages of evidence-based recommendations. Stroke is now the #4 leading cause of death in the U.S., with nearly 800,000 strokes annually.
1. Prehospital Recognition and EMS Care
- Public education tools: BE-FAST (Balance, Eyes, Face, Arm, Speech, Time) and FAST remain recommended for stroke recognition
- EMS providers should use validated prehospital stroke scales to identify large vessel occlusion (LVO)
- Mobile stroke units (MSUs) are now endorsed - they enable field CT imaging and prehospital thrombolysis, reducing time to treatment
- Prehospital notification of the receiving hospital is mandatory - enables pre-activation of the stroke team
- Regional triage systems: EMS should bypass non-capable hospitals when LVO is suspected and a thrombectomy-capable center is within a reasonable time frame
2. Emergency Department: Initial Evaluation
Time is Brain remains the core principle.
Time Targets
| Metric | Target |
|---|---|
| Door-to-imaging | Minimize delay; parallel processing recommended |
| Door-to-needle (IVT) | <60 minutes |
| Door-to-puncture (EVT) | <90 minutes |
Initial Assessment
- Rapid neurologic assessment using the NIH Stroke Scale (NIHSS)
- Parallel processing: imaging, labs, and clinical assessment run simultaneously
- Do not delay thrombolysis for nonessential labs (e.g., coagulation studies unless anticoagulant use is suspected)
- Vital signs, point-of-care glucose (hypoglycemia must be corrected before diagnosis is confirmed)
3. Neuroimaging
First-Line: Noncontrast CT (NCCT)
- Rapid and widely available
- Primarily used to rule out hemorrhagic stroke before thrombolysis
- ASPECTS (Alberta Stroke Program Early CT Score) helps quantify early ischemic change
Advanced Imaging (CT Perfusion / MRI)
- CT perfusion (CTP) or MRI diffusion/perfusion is used for:
- Extended time window patient selection (4.5-24 hours)
- Identification of salvageable ischemic penumbra
- Wake-up stroke workup
- CTA of head and neck: identifies LVO, guides EVT candidacy
4. Intravenous Thrombolysis (IVT)
Agent Selection - KEY 2026 UPDATE
Tenecteplase is now endorsed as equivalent/preferred to alteplase for most patients based on multiple RCTs (NOR-TEST, TRACE-3, AcT trials):
| Drug | Dose | Route | Advantage |
|---|---|---|---|
| Tenecteplase | 0.25 mg/kg (max 25 mg) | Single IV bolus | Easier to administer, non-inferior/potentially superior |
| Alteplase | 0.9 mg/kg (max 90 mg): 10% bolus, rest over 60 min | IV infusion | Long-established standard |
Standard Time Window
- IVT within 4.5 hours of symptom onset remains the standard
EXTENDED Time Window - KEY 2026 UPDATE
Based on EXTEND and TRACE-3 trials:
- IVT may be reasonable in patients 4.5 to 9 hours from last known well, or in wake-up strokes (within 9 hours from midpoint of sleep), if advanced imaging demonstrates salvageable ischemic penumbra (penumbra-to-core mismatch on CT perfusion or MRI)
- For LVO patients bridging to EVT: IVT within the extended window with salvageable tissue on advanced imaging may also be considered
Eligibility Criteria (Key Inclusions/Exclusions)
- Include: Measurable neurologic deficit, onset within time window, BP controlled (<185/110 before treatment)
- Exclude: Active intracranial hemorrhage, recent major surgery, recent intracranial/spinal surgery, uncontrolled severe hypertension, known bleeding diathesis
Blood Pressure Before/After IVT
- Pre-IVT: <185/110 mmHg required
- Post-IVT (first 24 hours): Maintain <180/105 mmHg
- NEW 2026: Intensive SBP lowering to <140 mmHg after IVT is NOT recommended - not associated with improved outcomes and may cause harm
BP Management Agents (from Rosen's EM textbook):
- SBP 180-230 or DBP 105-120: Labetalol 10 mg IV over 1-2 min, repeat q10-20 min (max 300 mg); or infusion 2-8 mg/min
- SBP >230 or DBP 121-140: Labetalol as above, OR Nicardipine 5 mg/h IV, titrate up by 2.5 mg/h every 5 min to max 15 mg/h; sodium nitroprusside if BP uncontrolled
5. Endovascular Therapy (EVT) / Mechanical Thrombectomy
Mechanical thrombectomy is the most impactful treatment for LVO stroke - expanded eligibility is a hallmark of the 2026 guidelines.
Indications (KEY UPDATES)
- LVO of the proximal anterior circulation (ICA, M1, M2 MCA) - Class I
- Posterior circulation LVO (basilar artery) - supported with favorable perfusion imaging
- Extended time window up to 24 hours with penumbra imaging (DAWN, DEFUSE-3 trials)
- Large infarct core (previously excluded): ASPECTS 0-5 - now eligible in selected patients based on newer trial data (SELECT2, ANGEL-ASPECTS, TENSION trials)
Transfer Protocols
- "Drip and ship" (IVT at primary center, transfer for EVT) vs. "mothership" (direct transfer to comprehensive stroke center) - guideline supports regional systems optimizing for fastest EVT access
- Direct transfer to EVT center preferred when transport time difference is <30 minutes
Technical Considerations
- Stent retrievers and aspiration catheters are both endorsed
- Target: TICI 2b/3 reperfusion
- Anesthesia: GA vs. conscious sedation - individualized decision (no definitive superiority of one approach)
6. Blood Glucose Management
- Persistent hyperglycemia in the first 24 hours is associated with worse outcomes
- Target: Blood glucose 140-180 mg/dL (insulin as needed)
- Hypoglycemia (<60 mg/dL) must be treated immediately with IV dextrose
- NEW 2026: Less aggressive glycemic management endorsed - tight glucose control (targeting normoglycemia) is no longer recommended due to hypoglycemia risk
7. Antithrombotic Therapy
- Aspirin 325 mg within 24-48 hours for non-thrombolysis patients (after hemorrhage excluded)
- Do not give aspirin within 24 hours of IVT
- For minor stroke/high-risk TIA: Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days is endorsed
- Anticoagulation is generally not indicated in acute ischemic stroke for most patients due to hemorrhagic conversion risk; individualized for specific etiologies (e.g., cardiac source with high recurrence risk)
- Tirofiban (GpIIb/IIIa inhibitor): A 2025 NEJM trial (PMID: 40616232) evaluated early tirofiban after IVT - evidence is emerging but not yet incorporated into the 2026 guideline
8. Neuroprotection and Supportive Care
- Temperature: Treat fever (>38°C) with antipyretics; hypothermia not yet proven
- Oxygen: Supplemental O2 only if SpO2 <94%; routine supplemental O2 in non-hypoxic patients is not beneficial
- IV fluids: Isotonic saline (0.9% NaCl); avoid hypotonic fluids (worsen cerebral edema)
- DVT prophylaxis: Pneumatic compression devices on admission; LMWH after 24-48 hours if no hemorrhagic conversion
- Dysphagia screening before oral intake
- Statins: Continue if already on; start high-intensity statin early
9. Blood Pressure in Non-Thrombolysis, Non-EVT Patients
- Permissive hypertension: Allow BP up to 220/120 mmHg in the first 24-48 hours (supports collateral flow to penumbra)
- Treat BP >220/120 only if: hypertensive emergency, aortic dissection, MI, or pre-eclampsia
- After 24-48 hours: Begin BP lowering, target <130/80 for long-term secondary prevention
10. Stroke Systems of Care
- Certifications: Primary Stroke Centers (PSC), Thrombectomy-Capable Stroke Centers (TSC), Comprehensive Stroke Centers (CSC)
- Regional stroke networks with teleneurology (telestroke) endorsed for resource-limited settings
- Quality metrics include door-to-needle time, door-to-puncture time, and TICI 2b/3 rates
11. KEY NEW ADDITIONS in 2026
| Feature | What's New |
|---|---|
| Tenecteplase | Now endorsed as the preferred/equivalent IVT agent (single bolus dosing) |
| Extended IVT window | Up to 9 hours with CT perfusion mismatch (EXTEND, TRACE-3) |
| Large infarct EVT | Thrombectomy now supported even with large core infarcts (ASPECTS 0-5) in select patients |
| Post-IVT BP | Intensive lowering to <140 mmHg NOT recommended |
| Glycemic targets | Less aggressive; 140-180 mg/dL target maintained, tight control abandoned |
| Mobile stroke units | Formally endorsed to reduce door-to-treatment time |
| Pediatric stroke | First detailed pediatric stroke recommendations included |
| Equity focus | Explicit recommendations to address disparities in stroke care access |
Supporting Recent Evidence
- Tenecteplase meta-analysis 4.5-24h, Stroke Jan 2026 (PMID 41078125) - supports extended window TNK use
- Tenecteplase vs. alteplase in EVT, AJNR 2025 (PMID 40750339) - TNK associated with better first-pass reperfusion
- Early tirofiban after IVT, NEJM Sept 2025 (PMID 40616232) - emerging adjunct antiplatelet strategy
Citation: Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2026. doi:10.1161/STR.0000000000000513
For a video overview of the guideline by the authors:
Cardiormbolic stroke management as per ACA 2019 and updates in 2026
Finding Sources
Searching the Web
cardioembolic stroke management 2026 AHA ASA guidelines atrial fibrillation anticoagulation PFO
Searching PubMed
"cardioembolic stroke" AND "anticoagulation" AND "atrial fibrillation"
Reading File
Reading File
Reading Web Page
https://www.stroke-manual.com/cardioembolic-stroke
Searching PubMed
"cardioembolic stroke" AND "anticoagulation" AND "guidelines"
Reading File
Searching the Web
2026 AHA ASA stroke guideline cardioembolic anticoagulation timing AF PFO closure LAAO DOAC updates
Searching PubMed
"atrial fibrillation" AND "stroke" AND "anticoagulation timing" AND "acute"
Reading Web Page
https://www.ahajournals.org/doi/10.1161/STR.0000000000000513
Finding Sources
Reading Article
PMID: 41449918
I now have comprehensive, well-sourced data across all relevant domains. Let me compile the full structured answer.
Cardioembolic Stroke: Management Per 2019 AHA/ASA Guidelines + 2026 Updates
Primary sources:
- Harrison's Principles of Internal Medicine, 22nd Ed. (2025, McGraw Hill)
- Fuster & Hurst's The Heart, 15th Ed.
- 2026 AHA/ASA Guideline (Prabhakaran S et al., Stroke, Jan 26 2026. doi:10.1161/STR.0000000000000513)
- 2021 AHA/ASA Guideline for Prevention of Stroke in Patients with Stroke/TIA
Overview: What Is Cardioembolic Stroke?
Cardioembolism accounts for ~20-30% of all ischemic strokes (up to 40% in some populations). The left atrial appendage (LAA) is the predominant source of emboli. Characteristic features include:
- Sudden onset with maximum deficit at onset
- Cortical involvement, multiple territory infarcts
- Hemorrhagic transformation (petechiae to frank ICH) due to reperfusion into ischemic territory
- Common embolic targets: intracranial ICA, MCA (stem or branches), PCA, basilar artery
- Small emboli may produce only TIA; large emboli (3-4 mm) occlude MCA stem causing large hemispheric infarcts - Harrison's 22E
Etiologies and Risk Stratification
HIGH-RISK Sources (anticoagulation standard of care)
| Condition | Risk Level | Treatment |
|---|---|---|
| Non-valvular atrial fibrillation | ~5% annual stroke risk | DOAC (preferred) or warfarin |
| Valvular AF / rheumatic mitral stenosis | High | Warfarin (INR 2.5-3.5); DOACs NOT approved |
| LA/LAA thrombus | High | Anticoagulation |
| LV thrombus | High | Warfarin (INR 2-3) x 3 months minimum |
| Recent anterior MI + reduced EF | ~2% in 4 weeks; 15% with LV thrombus | Warfarin 3 months |
| Mechanical prosthetic valve | High | Warfarin + aspirin |
| Ischemic cardiomyopathy with EF <15% | High | Consider anticoagulation |
MODERATE-RISK / INVESTIGATIONAL Sources
| Condition | Guidance |
|---|---|
| Systolic HF (EF <15%), no thrombus | Anticoagulation may be of value |
| Non-bacterial thrombotic endocarditis | Anticoagulation (especially with hypercoagulability) |
| Papillary fibroelastoma (if surgery contraindicated) | Anticoagulation |
| Atrial cardiopathy in ESUS | Under study |
ANTICOAGULATION CONTRAINDICATED
| Condition | Treatment Instead |
|---|---|
| Infective endocarditis | Antibiotics; no anticoagulation |
| Atrial myxoma | Surgical resection |
ANTIPLATELET-BASED
| Condition | Treatment |
|---|---|
| Bioprosthetic aortic/mitral valve | ASA 75-100 mg daily (after initial 3-6 months warfarin) |
| Aortic arch atheroma | Antiplatelet |
| PFO (closed surgically/percutaneously) | ASA post-closure |
- Fuster & Hurst's The Heart, 15th Ed., p. 822
1. Atrial Fibrillation: Cornerstone of Cardioembolic Stroke
Risk Assessment: CHA₂DS₂-VASc Score
| Score | Annual Stroke Risk (non-treated) |
|---|---|
| 0 | ~0% |
| 1 | ~1.3% |
| 2 | ~2.2% |
| ≥3 | Escalating - warfarin NNT for secondary prevention = 13 |
AF confers 1.8-2.9x relative risk of stroke; anticoagulation provides 68% relative risk reduction (warfarin), vs 21% with aspirin alone. - Harrison's 22E
Drug Choice (per 2019 and unchanged in 2026)
- DOACs are first-line for non-valvular AF: dabigatran, rivaroxaban, apixaban, edoxaban
- Warfarin (target INR 2.0-3.0) for rheumatic mitral stenosis, mechanical valves
- Warfarin NOT DOACs in valvular AF (rheumatic)
- Aspirin alone is inadequate for stroke prevention in AF
2. Anticoagulation TIMING After Acute Cardioembolic Stroke
2019 AHA/ASA Guideline: The "1-3-6-12 Rule"
The traditional approach was empirical, based on stroke severity:
| Stroke Severity | Timing to Start Anticoagulation |
|---|---|
| TIA | Immediately (same day) |
| Minor stroke (NIHSS ≤8) | 3 days |
| Moderate stroke (NIHSS 8-15) | 6 days |
| Major stroke (NIHSS ≥16) | 12-14 days |
This was based on concern for hemorrhagic transformation with early anticoagulation.
2019 recommendation: Initiation of anticoagulation in AF-related stroke within 4-14 days depending on size; avoid urgent/emergency anticoagulation unless high recurrence risk.
2026 UPDATE: ELAN, OPTIMAS, TIMING Trials - Major Shift
Three landmark RCTs now inform the 2026 guideline:
ELAN Trial:
- Early DOAC (within 48h for minor/moderate; day 6/7 for major) vs. later DOAC
- Result: Numerical but non-significant reduction in recurrent stroke, no increase in hemorrhagic transformation (risk difference -1.18, 95% CI -2.84 to 0.47)
OPTIMAS Trial (3648 patients):
- Early DOAC (≤4 days) vs. delayed DOAC (7-14 days)
- Result: Early was noninferior to delayed - no increase in hemorrhagic events
TIMING Trial:
- Early (≤4 days) vs. delayed (5-10 days)
- Primary outcome: 6.9% early vs. 8.7% delayed - noninferior
2026 Recommendation (NEW):
"Among patients with AIS and AF selected for anticoagulation post-stroke, a strategy of early DOAC initiation rather than delayed initiation is safe, although the efficacy in early recurrent stroke prevention is not yet established."
- Early DOAC (within 48h-4 days) is now safe and preferred for minor-moderate strokes
- The strict 1-3-6-12 day rule is no longer mandatory - individualized timing based on:
- Stroke size (infarct volume on DWI)
- Hemorrhagic transformation risk
- CHA₂DS₂-VASc score and recurrence risk
- Heparin bridging is NOT recommended (no proven benefit, increased bleeding risk)
Supporting meta-analysis (PMID 41449918): Early anticoagulation associated with significantly lower recurrent ischemic stroke (OR 0.72, 95% CI 0.55-0.96) without significant increase in ICH.
3. Mechanical Prosthetic Valves
- Warfarin + Aspirin 75-100 mg remains standard - DOACs are contraindicated (RE-ALIGN trial showed harm)
- Target INR: 2.5-3.5 (mitral); 2.0-3.0 (aortic) - individualized per valve type and position
- Interruption for procedures: bridging with LMWH or UFH required given high thromboembolic risk
4. Patent Foramen Ovale (PFO)
2019 AHA/ASA and 2021 Secondary Prevention Guideline
Transcatheter PFO closure is recommended (Class IIa) for:
- Patients aged 18-60 years with cryptogenic ischemic stroke
- High probability of paradoxical embolism: large right-to-left shunt, atrial septal aneurysm (ASA), high RoPE score
- After exclusion of other stroke etiologies (especially atrial fibrillation by prolonged monitoring)
Evidence base: RESPECT, CLOSE, REDUCE, DEFENSE-PFO trials all showed benefit vs. antiplatelet therapy alone in high-risk patients.
Post-closure: Dual antiplatelet for 3 months, then aspirin long-term. Anticoagulation is an alternative to closure in selected high-risk cases.
2026 Update: PFO closure recommendations are maintained with stronger emphasis on:
- Multidisciplinary evaluation (vascular neurologist + cardiologist)
- High RoPE score (≥7) as key selection criterion
- Benefit is similar in patients under 45 and 45-60 years
- Consideration in 60-65 years without significant vascular risk factors (AAN guidelines, Level C)
- Shunt size (large shunt) is more predictive of benefit than presence of ASA alone
5. Left Atrial Appendage Occlusion (LAAO)
2019: Limited to anticoagulation-ineligible patients
WATCHMAN device was approved for AF patients with contraindication to long-term anticoagulation (major bleeding, falls, etc.).
2026 Update: Evolving Role
- LAAO (WATCHMAN FLX) is a Class IIb alternative for patients with AF who:
- Have contraindications to long-term anticoagulation
- Or have high bleeding risk on DOACs
- Recent meta-analyses and the COMPARE-LAAO trial (PMID 41400760) show LAAO non-inferior or superior to standard of care in high-risk patients
- Left atrial appendage closure after AF ablation is gaining evidence (NEJM 2025)
- DOACs remain first-line; LAAO is not yet a routine alternative to DOACs for low-bleeding-risk patients
6. Device-Detected Atrial Fibrillation (DDAF) - NEW in 2026
- Pacemakers, ICDs, implantable loop recorders detecting subclinical AF (AHRE - atrial high-rate episodes)
- 2026 guidance: DDAF with episodes >6 minutes (particularly >24 hours) confer stroke risk and warrant consideration for anticoagulation
- CHA₂DS₂-VASc + episode duration used to individualize decision
- Ongoing trials (ARTESIA, NOAH-AFNET 6) informing this area
7. LV Thrombus After MI
| Setting | 2019 | 2026 |
|---|---|---|
| Acute anterior MI + LV thrombus confirmed | Warfarin 3+ months (INR 2-3) | Maintained; DOACs emerging |
| Reduced EF <50%, no confirmed thrombus | Consider warfarin 3 months | Safety of DOACs still uncertain |
| DOACs in LV thrombus | Limited evidence | Recent RCTs (COMMANDER HF, etc.) - growing DOAC data, still guideline-uncertain |
8. Hemorrhagic Transformation After Cardioembolic Stroke
- Petechial hemorrhage: clinically insignificant, not a contraindication to anticoagulation
- Frank parenchymal hematoma (PH-2): Delay anticoagulation; reassess risk vs. benefit
- All patients require follow-up MRI/CT at 48-72h before starting or resuming anticoagulation when major hemorrhagic transformation is present
Summary: 2019 vs. 2026 Key Differences
| Topic | 2019 AHA/ASA | 2026 Update |
|---|---|---|
| Anticoagulation timing (AF) | 1-3-6-12 day rule by stroke severity | Early DOAC (≤4 days) now safe; individualized approach endorsed |
| DOAC in AF | Preferred over warfarin (non-valvular) | Maintained; tenecteplase update also relevant |
| Post-IVT BP | No specific guidance on lower limit | Do NOT target SBP <140 mmHg aggressively |
| PFO closure | Class IIa <60 years, cryptogenic | Maintained; refined by shunt size and RoPE score |
| LAAO | Anticoagulation-ineligible patients only | Broader role under study; Class IIb for selected high-risk patients |
| Device-detected AF | Limited guidance | Formal recommendations for DDAF/AHRE anticoagulation decisions |
| Glycemic management | Tight control encouraged | Less aggressive; 140-180 mg/dL target; avoid hypoglycemia |
| Heparin bridging | Not recommended | Confirmed: NOT recommended |
Key citations:
- 2026 AHA/ASA Stroke Guideline - Prabhakaran S et al., Stroke 2026
- Anticoagulation timing meta-analysis (PMID 41449918) - Moawad et al., Clin Appl Thromb Hemost 2025
- OPTIMAS trial CKD subgroup (PMID 40402086) - Nash PS et al., Stroke 2025
- Harrison's Principles of Internal Medicine, 22nd Ed., Chapter 438
- Fuster & Hurst's The Heart, 15th Ed., p. 822
This is a shared conversation. Sign in to Orris to start your own chat.